Xgene raises ¥250M Series D to fund US pain-drug trial

What's the deal? Xgene PharmaceuticalDealroom has a profile for this one. Try Dealroom →, based in Shanghai, has closed a ¥250 million (≈$37 million) Series D round. Yifeng CapitalDealroom has a profile for this one. Try Dealroom → and GTJA Investment co-led, with Jiaxing Yuanfan and Real Capital Global also participating.

What's the endgame? The company will spend most of the money advancing its lead product, XG005, into Phase III acute-pain clinical trials in the US. The round also supports continued development of its core pipeline and global expansion.

The signal: The raise underscores Chinese biotech's push to run late-stage trials in the US and build products for global markets, rather than staying domestic.

Image credit: zhouxuan12345678